Our licensing agreement with @HUTCHMED gives us the potential to further our goal of making transformative treatments more accessible for patients who need them. Through this partnership, we aim to offer a potential new treatment option to people with refractory metastatic #ColorectalCancer who have only limited or ineffective treatment options.
The insight and guidance from patients and care partners alike is invaluable in our efforts to increase access to transformative medicines. We look forward to expanding our advocacy programs to include #ColorectalCancer to better support the community. Read the release https://lnkd.in/dXqWeJAJ and hear more below:
Great to see the progress that FRU is bringing to the CRC space. Amazing to see Takeda take the baton and lead the charge for those patients that have limited choice. Cheers and looking forward to hearing about the success!